Two federal lawsuits filed within weeks of a nationwide infant formula recall have thrust the Nara Organics infant formula lawsuit into the center of one of the most urgent product liability stories of 2026. With four confirmed infant botulism cases across three states, a CDC/FDA-confirmed bacterial contaminant found in a recalled product, and no MDL yet formed, families and legal advocates are moving fast — and the evidentiary record is still growing.
The Recall: What Happened and When
On June 12, 2026, the FDA and CDC contacted Nara Organics after identifying three confirmed infant botulism cases potentially linked to the company’s Whole Milk Organic Powdered Infant Formula. The very next day — June 13, 2026 — Nara Organics issued a voluntary recall of all lots and both can sizes of its powdered infant formula, covering every unit sold in the United States.
The formula had been manufactured in Europe — specifically Germany — and sold exclusively through Target retail locations, Target.com, and Nara.com between July 2025 and June 2026. Nara had aggressively marketed itself as “the first and only USDA-certified organic whole-milk infant formula” available to American consumers — a premium positioning that plaintiffs now argue placed the exact ingredient responsible for contamination risk at the heart of the brand’s identity.
By early July 2026, the California Department of Public Health (CDPH) confirmed the presence of Clostridium botulinum in an opened can of Nara formula recovered from one of the affected infants’ homes — a finding that coincided with CDC adding a fourth confirmed case and bringing California’s total to two cases. Testing of unopened cans from the same production lot continued, with results still pending from the FDA. Notably, whole genome sequencing evidence has since indicated a common source of contamination between the Nara outbreak and the 2025 ByHeart outbreak linked to infant formula, a connection that regulators and plaintiffs’ attorneys are closely monitoring.
On August 27, 2026, FDA and CDC jointly announced that the infant botulism outbreak was officially over, with a final total of four confirmed cases. That declaration closes the acute public health chapter — but it does not close the legal one.
The Outbreak: Four Confirmed Cases, Three States
Public health authorities confirmed a total of four infant botulism cases linked to Nara Organics formula, with the outbreak officially declared over on August 27, 2026. All four victims are male infants who fell ill between April and May 2026. The Nara Organics infant formula lawsuit filings draw heavily on this epidemiological data to establish causation. Below is a summary of the confirmed outbreak data:
| Detail | Data |
|---|---|
| Total confirmed cases (final) | 4 |
| States affected | California (2), Pennsylvania (1), Washington (1) |
| Ages of affected infants | 68–153 days old |
| Sex of affected infants | All male |
| Period of illness onset | April–May 2026 |
| Deaths reported | 0 |
| C. botulinum confirmed in product | Yes — opened can, CDPH confirmation (~July 6, 2026) |
| Outbreak declared over | August 27, 2026 (FDA/CDC joint announcement) |
| Recall scope | All lots, both can sizes, June 13, 2026 |
| Prior comparable outbreak | ByHeart (~48 infants, 17 states, beginning November 2025) |
Infant botulism almost exclusively affects babies under 12 months old, with the highest risk concentrated in infants under six months — precisely the age group Nara’s formula was designed to feed. The only approved treatment is BabyBIG antitoxin, a medication produced exclusively by the California Department of Public Health, underscoring how rare and resource-limited the medical response to this condition remains. Adding to the scientific complexity, whole genome sequencing has pointed toward a shared contamination source between the Nara cases and the earlier ByHeart outbreak, raising broader questions about supply chain oversight across the infant formula industry.
The Lawsuits: Two Federal Filings in Less Than Three Weeks
Two separate federal lawsuits have been filed against Nara Organics in connection with the recall and outbreak, with both actions naming Target as a co-defendant given the retailer’s role as the exclusive U.S. distribution channel for the formula.
Marler Clark Personal Injury Suit — Eastern District of Pennsylvania
The first lawsuit was filed in the Eastern District of Pennsylvania by the food safety litigation firm Marler Clark on behalf of a Pennsylvania family whose infant was among the confirmed botulism cases. The complaint alleges strict product liability, negligence, and breach of warranty, asserting that Nara Organics placed an unreasonably dangerous product into the stream of commerce and that Target, as the exclusive retail distributor, shares liability for the harm caused.
Second Lawsuit — Washington Federal Court
On July 23, 2026, a second lawsuit was filed in Washington federal court by plaintiffs Jin Nam and Jisun Lee against Nara Organics, Target, and John Doe defendants. The Washington filing adds to the growing litigation footprint and signals that counsel for injured families are pursuing claims in multiple jurisdictions rather than waiting for a centralized MDL to form. Both complaints cite the CDC’s epidemiological findings, the CDPH laboratory confirmation of Clostridium botulinum in an opened can of Nara formula, and the whole genome sequencing data linking the Nara outbreak to the prior ByHeart contamination event as key evidentiary pillars.
The Constructive Notice Argument: What Did Nara Know, and When?
One of the most consequential legal questions in the Nara Organics infant formula lawsuit litigation is whether the company had — or should have had — advance knowledge of a contamination risk before the June 2026 recall. Plaintiffs’ attorneys are focusing on the timeline of the ByHeart outbreak, which began in November 2025 and ultimately affected approximately 48 infants across 17 states. Whole genome sequencing evidence suggesting a common contamination source between ByHeart and Nara makes this argument significantly stronger: if the two outbreaks share a microbial fingerprint, it raises the question of whether Nara had a duty to investigate its own supply chain after the ByHeart recall drew industry-wide attention to the risks of contaminated powdered infant formula.
Constructive notice doctrine holds that a manufacturer can be deemed to have known about a defect if a reasonable company in its position would have discovered it through ordinary diligence. Given that the ByHeart outbreak was extensively covered by regulators and trade press beginning in late 2025, plaintiffs will argue that Nara had both the knowledge and the opportunity to conduct enhanced testing of its formula — and failed to do so.
The Regulatory Gap: Why FDA Rules May Have Enabled This Outbreak
The Nara Organics recall has renewed calls for stricter federal oversight of powdered infant formula, a product category that the FDA regulates but does not require to be sterile. Current regulations permit the presence of certain bacterial loads in powdered formula so long as they fall below established thresholds — a framework that critics argue is insufficient given the extreme vulnerability of the infant population consuming the product.
In March 2026, U.S. Representative Rosa DeLauro introduced the Infant Formula Safety Modernization Act, bipartisan legislation that would tighten FDA oversight of powdered formula manufacturing, strengthen recall authority, and require enhanced pathogen testing protocols. As of mid-2026, the bill is under Congressional consideration, and the Nara outbreak has given its proponents renewed urgency to push for passage. Legal advocates representing affected families have noted that stronger pre-market testing requirements — had they been in place — might have caught the contamination before any infant was harmed.
The FDA’s own enforcement record on infant formula has been under scrutiny since the 2022 Abbott Nutrition crisis, which triggered nationwide shortages and exposed significant gaps in the agency’s inspection and recall infrastructure. The Nara situation suggests those gaps have not been fully closed, and plaintiffs’ attorneys are expected to use the regulatory history as background context to argue that the industry has been on constructive notice of systemic contamination risks for years.
What Injured Families Should Do Right Now
If your infant was fed Nara Organics Whole Milk Organic Powdered Infant Formula and experienced symptoms consistent with botulism — including constipation, weakness, poor feeding, a weak cry, or difficulty breathing — there are specific steps you should take immediately to protect both your child’s health and any potential legal claim.
- Seek medical attention immediately if your child has not already been evaluated. Infant botulism is treatable, but early intervention with BabyBIG antitoxin is critical to limiting neurological harm.
- Preserve the formula container. Do not discard any remaining formula, the can, the lid, the scoop, or the packaging. Even an opened can — like the one in which CDPH confirmed C. botulinum — can constitute critical physical evidence.
- Document everything. Retain all purchase receipts, order confirmations, medical records, hospital bills, and any photographs of the product or your child’s condition. If you received the formula as a gift, try to obtain documentation from the purchaser.
- Report to the FDA. File a MedWatch report at fda.gov/safety/medwatch. This creates an official record and contributes to the agency’s ongoing investigation.
- Consult a mass tort attorney promptly. While the outbreak has been declared over, the legal proceedings are still in early stages. Statutes of limitations for product liability claims vary by state, and the evidentiary record is still being developed. Early consultation preserves your options.
Frequently Asked Questions: Nara Organics Infant Formula Lawsuit
What formula is included in the Nara Organics recall?
The June 13, 2026 recall covers all lots and both can sizes of Nara Organics Whole Milk Organic Powdered Infant Formula sold in the United States. The product was sold exclusively through Target stores, Target.com, and Nara.com between July 2025 and June 2026. If you purchased any Nara Organics powdered infant formula during that period, it is covered by the recall regardless of lot number or can size.
How do I know if my baby’s illness is connected to the Nara Organics outbreak?
Infant botulism presents with a characteristic cluster of symptoms: constipation is typically the first sign, followed by generalized weakness, a weak or altered cry, poor sucking and feeding, drooping eyelids, and in severe cases, respiratory distress. If your infant consumed Nara Organics formula and experienced any of these symptoms between approximately March and July 2026, you should seek medical evaluation and consult a product liability attorney. Laboratory confirmation of C. botulinum in a product sample or in your child’s stool is the gold standard for establishing case linkage, but clinical diagnosis combined with product exposure history can be sufficient to support a legal claim.
Can I still file a claim if I don’t have the original can?
Yes. While preserving the physical product is ideal, the absence of the original container does not bar a legal claim. Purchase records — including credit card statements, Target Circle loyalty account history, and online order confirmations — can establish that your family purchased the recalled product. Medical records documenting your infant’s diagnosis, combined with epidemiological data linking the outbreak to Nara Organics formula, can establish causation even without the physical can.
Why is whole milk powder specifically dangerous for infant botulism?
Whole milk powder is a low-moisture, low-water-activity ingredient that creates an environment in which Clostridium botulinum spores can survive for extended periods. Unlike liquid formula, which undergoes sterilization processes that kill spores, powdered formula is not required to be sterile under current FDA regulations. Whole milk powder — as opposed to skim milk powder — has a higher fat content that may further complicate pathogen detection during routine testing. Nara’s brand identity was built around whole milk as a premium differentiator, which plaintiffs argue means the company had a heightened duty to understand and mitigate the specific contamination risks associated with that ingredient.
Is there already a class action MDL for the Nara Organics lawsuit?
As of the date of this publication, no Multi-District Litigation (MDL) has been established for the Nara Organics infant formula lawsuits. With two federal filings in Pennsylvania and Washington, and the outbreak officially concluded with four confirmed cases, it remains to be seen whether additional lawsuits will be filed in sufficient numbers to warrant MDL consolidation. Families should not wait for an MDL to consult with an attorney — individual claims can proceed independently, and early filers often have strategic advantages in terms of discovery access and case positioning.
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.